Guildford, UK, 12 January 2007: ReNeuron Group plc (LSE: RENE) today provides a further update regarding its recently filed Investigational New Drug (IND) application to commence a Phase I clinical study for its ReN001 stem cell therapy for stroke.
Guildford, UK, 12 January 2007: ReNeuron Group plc (LSE: RENE) today provides a further update regarding its recently filed Investigational New Drug (IND) application to commence a Phase I clinical study for its ReN001 stem cell therapy for stroke.
